Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 15, 2003

View Archived Issues

Phase II trial studies Acclaim for chronic angina

Avigen licenses technology for treatment of chronic pain from U. of Colorado

Encouraging preclinical results for BioSante's BioAir CAP-delivered insulin

USAMRIID to screen Kemin molecules for SARS and smallpox

Strategic agreement for commercialization of Australian ddRNAi efforts

Promising animal data announced for CEL-1000 in malaria

National Eye Institute supports Genvec PEDF work through SBIR grants

Spring Bank acquires rights to MBI-1313 for HBV from Micrologix

Q1 2004 IND filing planned for phase I trial of ZFP VEGF therapeutic

ThGRF does not improve functional recovery following hip fracture surgery

Sankyo selects target for development in Tularik GPCR collaboration

Bayer claims two series of PDE4 inhibitors for COPD and asthma

New bombesin antagonists and their use in sexual disorders reported by Pfizer

Roche researchers prepare and test new dimeric antitumor agents

Merck scientists identify new GABA(A) ligands for anxiety, convulsions, etc.

Novel VLA-4 inhibitors, their preparation and use described by UCB

Novel Pin1 inhibitors designed and tested by German researchers

AVR-118 inhibits progression of EAE in rats

CIMA plans phase III for OraVescent Fentanyl, outlicenses in Japan

Promising new antisickling agent 5-HMF: in vitro and in vivo studies

EiRx to evaluate SR Pharma's inositol phosphoglycans

Monoclonal antibody targeting CD44 induces differentiation and apoptosis in AML cells

OrCel achieves primary and secondary endpoints in venous leg ulcer study

New proof-of-principle phase II study of PYM-50028 in Alzheimer's disease

Novel antiplatelet compound acts by inhibiting protein palmitoylation

High clinical and microbiological response rates for iclaprim in cSSTs

Potent and selective human chymase inhibitor selected from new class of compounds

New concepts in schizophrenia: neuroprotection with EPO

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...